Clinical drug testing fell by over 50% in spring of 2020 due to the COVID-19 pandemic, according to a new study from Quest Diagnostics®. At the same time, the proportion of samples testing positive for dangerous illicit drugs and drug combinations rose.
In mandated tests of employees in safety-sensitive jobs, marijuana had the highest rate of drug positivity, followed by opioids and amphetamines, according to the 2020 Quest Diagnostics Drug Testing Index™ report. The report includes data from over 2.4 million tests from January to December 2019 of workers in safety-sensitive positions undergoing federally mandated drug tests. These include workers in the airline, transportation, and marine industries, among others.
The rate of drug test positivity in the workforce hit a 16-year high in 2019, according to data from the annual Quest Diagnostics Drug Testing Index™ report. Data for the report are drawn from nearly 9 million urine drug tests performed during the year by Quest, the world’s leading provider of diagnostic information services. Overall, 4.5% of samples tested indicated use of an illicit drug.
New options for Specimen Collection from Quest Diagnostics Drug Monitoring. Clinical Drug Monitoring is a critical tool to measure and assess prescription compliance and help identify drug misuse. With the ongoing COVID-19 pandemic and social distancing, many patients are not getting to their physicians’ offices for the drug monitoring testing they need.
Drug Mixing: The Most Prevalent, and Dangerous, Form of Drug Misuse. Is your patient mixing prescribed medications with non-prescribed or illicit drugs? Most clinicians underestimate the likelihood that their patients are engaging in this most-prevalent type of prescription drug misuse. But what they don’t know could hurt their patients.